Autor segons l'article: Holmes, M.V. Simon, T. Exeter, H.J Folkersen, L. Asselbergs, F.W. Guardiola, M. Cooper, J.A. Palmen, J. Hubacek, J.A. Carruthers, K.F. Horne, B.D. Brunisholz, K.D. Mega, J.L. Van Iperen, E.P. Li, M. Leusink, M. Trompet, S. Verschuren, J.J. Hovingh, G.K. Dehghan, A. Nelson, C.P. Kotti, S. Danchin, N. Scholz, M. Haase, C.L. Rothenbacher, D. Swerdlow, D.I. Kuchenbaecker, K.B. Staines-Urias, E. Goel, A. Van 't Hooft, F. Gertow, K. De Faire, U. Panayiotou, A.G. Tremoli, E., Baldassarre, D. Veglia, F. Holdt, L.M. Beutner, F. Gansevoort. R.T. Navis, G.J. Mateo, L.I. Breitling, L.P. Brenner, H. Thiery, J. Dallmeier, D. Franco-Cereceda, A. Boer, J.M. Stephens, J.W. Hofker, M.H. Tedgui, A. Hofman, A. Uitterlinden, A.G. Adamkova, V. Pitha, J. Onland-Moret, N.C. Cramer, M.J. Nathoe, H.M. Spiering, W. Klungel, O.H. Kumari, M. Whincup, P.H. Morrow, D.A. Braund, P.S. Hall, A.S. Olsson, A.G. Doevendans, P.A. Trip, M.D. Tobin, M.D. Hamsten, A. Watkins, H. Koenig, W. Nicolaides, A.N. Teupser, D. Day, I.N. Carlquist, J.F. Gaunt, T.R. Ford, I. Sattar, N. Tsimikas, S. Schwartz, G.G. Lawlor, D.A. Morris, R.W. Sandhu, M.S. Poledne, R. Maitland-van der Zee, A.H. Khaw, K.T. Keating, B.J. Van der Harst, P. Price, J.F. Mehta, S.R. Yusuf, S. Witteman, J.C. Franco, O.H. Jukema, J.W. De Knijff, P. Tybjaerg-Hansen, A. Rader, D.J. Farrall, M. Samani, N.J. Kivimaki, M. Fox, K.A. Humphries, S.E. Anderson, J.L. Boekholdt, S.M. Palmer, T.M. Eriksson, P. Paré, G. Hingorani, A.D. Sabatine, M.S. Mallat, Z. Casas, J.P. Talmud, P.J.
Departament: Medicina i Cirurgia
e-ISSN: 1558-3597
Autor/s de la URV: Guardiola, M. Michael V Holmes, Lasse Folkersen, Tabassome Simon
Paraules clau: Cardiovascular diseases; Drug development; Epidemiology; Genetics; Mendelian randomization
Resum: This study sought to investigate the role of secretory phospholipase A2(sPLA2)-IIA in cardiovascular disease. Higher circulating levels of sPLA2-IIA mass or sPLA2enzyme activity have been associated with increased risk ofcardiovascular events. However, it is not clear if this association is causal. A recent phase III clinical trial of an sPLA2inhibitor (varespladib) was stopped prematurely for lack of efficacy
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 0735-1097
Pàgina final: 1976
Volum de revista: 62
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
Enllaç font original: https://www.sciencedirect.com/science/article/pii/S0735109713027782?via%3Dihub
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
DOI de l'article: https://doi.org/10.1016/j.jacc.2013.06.044
Entitat: Universitat Rovira i Virgili.
Any de publicació de la revista: 2013
Pàgina inicial: 1966